Manufacturing: Page 2
-
Pharma’s rare disease rush
Biogen’s acquisition of Reata Pharmaceuticals is the latest in a string of high-dollar rare disease deals over the last few months. What does it mean for industry?
By Meagan Parrish , Karissa Waddick • Aug. 14, 2023 -
Biosimilar makers split strategies in bid to take on top-selling Humira
In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.
By Jonathan Gardner • July 26, 2023 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Q&A
As biologics boom, here’s how manufacturers are keeping up
Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.
By Michael Gibney • July 19, 2023 -
Boosting the cell and gene therapy workforce with a skilled, localized approach
Experts provide a roadmap for how the industry can work with academia to ensure a robust talent pipeline for the burgeoning field.
By Karissa Waddick • June 15, 2023 -
Drugmakers feel the squeeze as cost pressures mount
Supply chain challenges have eased — but now inflation and manufacturing complexity are triggering a new sense of urgency to bring costs down.
By Kelly Bilodeau • June 5, 2023 -
Strangers in a strange land: 8 unlikely companies making plays in pharma
How these consumer and service companies are tapping into major trends in the biopharma industry.
By Karissa Waddick • May 22, 2023 -
Profile
A day in the life of a pharma exec: Lyndra’s Patricia Hurter
How the CEO starts each day with a ride on one of her horses, reduces daily meetings and uses her network to get through crises like the SVB Bank collapse.
By Meagan Parrish • May 17, 2023 -
Where one unicorn struggled, another biotech is aiming for a diabetes win
Intarcia looked poised to break into a lucrative diabetes implant market but has been dogged by safety issues — now Vivani thinks it’s found a way to succeed.
By Kelly Bilodeau • April 10, 2023 -
Staff shortages cause slowdowns in booming cell and gene therapy market
New reports highlight the need for more targeted biotech education curriculums to shore up a sustainable workforce.
By Karissa Waddick • April 3, 2023 -
Q&A // Biotech Spotlight
Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck
The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.
By Taren Grom • Jan. 9, 2023 -
Opinion
The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences
A preview of the top trends on the minds of industry and market leaders for the new year.
By Taren Grom • Jan. 3, 2023 -
Q&A
A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’
The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug.
By Meagan Parrish • Dec. 6, 2022 -
While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help
Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.
By Michael Gibney • Nov. 8, 2022 -
How Europe’s energy crisis is impacting pharma
Inflationary pressures and rising energy costs could further expedite the movement of generics manufacturing from Europe to Asia if governments don’t step in.
By Karissa Waddick • Nov. 2, 2022 -
Sponsored by Phil, Inc.
Developing a channel strategy that optimizes gross to net
Today, pharma manufacturers face unprecedented GTN challenges. To unlock sustainable brand growth, a value-aligned channel strategy is pivotal.
Oct. 31, 2022 -
Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots
The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.
By Meagan Parrish • Oct. 25, 2022 -
5 impactful drug trial failures from the last year
Major recent trial flops and what they mean for companies, patients and the industry.
By Meagan Parrish • Oct. 19, 2022 -
Making Moves
C-suite shake-ups at 23andMe, Moderna signal new stages of growth
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
By Karissa Waddick • Oct. 5, 2022 -
Q&A
It’s electric — speeding up the cell therapy process for scalability
To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.
By Alexandra Pecci • Oct. 4, 2022 -
Feds could soon bring COVID-style fight to superbug threat
COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.
By Karissa Waddick • Sept. 13, 2022 -
4 ways to nail the launch of your cell therapy
A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.
By Meagan Parrish • Aug. 10, 2022 -
The ‘alarming’ spread of Monkeypox — by the numbers
With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’
By Meagan Parrish • Aug. 8, 2022 -
Making Moves
Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires
How these latest executive personnel changes are impacting the industry.
By Karissa Waddick • Aug. 3, 2022 -
Q&A
A glimpse inside Bristol Myers Squibb’s integration with Celgene
Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.
By Meagan Parrish • Aug. 1, 2022 -
Pfizer's former R&D head takes on drug pricing misconceptions in new book
John LaMattina has something to say about the industry — and he hopes patients are listening.
By Meagan Parrish • July 19, 2022